OmniComm Systems' TrialOne Chosen by QPS for Phase I Clinic Automation

OmniComm Systems, Inc. (OTC:OMCM), announced that TrialOne(R) has been selected by QPS to automate subject recruitment, screening and enrollment in its early phase clinical pharmacology unit in Groningen, The Netherlands.

TrialOne(R) allows the Phase I recruitment team to keep track of advertising campaigns as well as a subject's interest in a particular study. Volunteers are enrolled into a study only after successfully passing inclusion/exclusion criteria allowing customizable study entry controls to be maintained. Communication in the form of letters, emails, text messages, or phone calls can be sent to subjects to remind them of upcoming screening and study visits. TrialOne(R) has a dynamic subject database that allows sites to maintain a pool of volunteers with only the data collection fields applicable to the site, meaning no more empty fields. Subject and study specific data remain separate but users can still securely query across datasets.

"We selected the TrialOne(R) Recruiting Module because it is a fit-for-purpose solution for Phase I subject recruiting. That means we will be able to keep record of our volunteers and patients and the system will support our ability to quickly contact, qualify, and enroll them for the study," said Ben Chien, CEO of QPS. "TrialOne(R) is a critical upgrade for our rapidly developing Phase I business in Europe."

TrialOne(R) is a web-based, mobile, clinic automation solution designed specifically for early-phase research. This computerized system facilitates screening, recruitment, appointment scheduling, source data capture, sample tracking and reporting. TrialOne(R) offers time-based data entry and automates many data collection activities via its ability to both print and scan barcodes, as well as to read data directly from medical devices such as blood pressure monitors. Furthermore, TrialOne's import and export features provide integration with Laboratory Information Management Systems (LIMS) for lab orders and results processing as well as full SAS export capability.

QPS provides fully integrated Phase I services ranging from protocol development, patient stratification/genotyping and clinical conduct to bioanalysis, data management/statistical analysis, PK/PD modeling and medical report writing. QPS is headquartered in Newark, DE and offers Phase I facilities in locations as diverse as Springfield, MO; South Miami, FL; Groningen, The Netherlands; Graz, Austria; Hyderabad, India; and Taipei, Taiwan.

"We are extremely pleased to be chosen by QPS to assist them with their clinical research needs," said Stephen Johnson, President and COO of OmniComm. "QPS has built up an excellent reputation in Phase I over the past ten years and has conducted hundreds of clinical studies involving thousands of volunteers for nationally and internationally recognized pharmaceutical and biotechnology companies. We are delighted to be partnering with them to offer solutions that will help them centralize and standardize the way in which they conduct research."

Safe Harbor Disclaimer

Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.